Roche got a big boost for its bid to position the leukemia drug GA101 (obinutuzumab) as a next-gen successor to its blockbuster Rituxan, posting late-stage data last night that showed that a combinati…
First Phase III Data on Obinutuzumab GA101 in one of the Most Commonly Diagnosed Blood Cancers Early Stage Data on Investigational AntiPDL1 Immunotherapy Genentech a mem…
Celgene has put another brick in the wall of positive late-stage data for apremalist as a new therapy for psoriatic arthritis, building on its new drug application at the FDA.
After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy (DMD) under wraps, GlaxoSmithKline ($GSK) has pulled back part of the covers to reveal tha…
